Improving the diagnosis of Hypophosphatasia (HPP)
A case-based, enduring format that enables multidisciplinary learners to apply HPP diagnostic strategies in realistic scenarios, reinforcing knowledge retention and improving clinical decision-making. Helping clinicians identify and manage HPP by aligning with diagnostic, referral, and therapeutic responsibilities within endocrinology, rheumatology, and primary care practice.
Target Audience
This activity is designed for an audience of Physicians.
Learning Objectives
- Recognize key clinical signs and biochemical markers suggestive of hypophosphatasia in children and adults
- Differentiate HPP from more common metabolic bone diseases to reduce diagnostic delays
- Apply evidence-based strategies to initiate appropriate diagnostic workups, including genetic and enzymatic testing
Commercial Support
This activity is supported from an independent medical education grant from Alexion Pharma GmbH.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Richard Keen, MB BS, BSc, PhD (faculty) | Advisor, Speaker | Alexion |
Rachel Lombardo, MD (faculty) | Advisor, Speaker | Alexion |
Researcher | BioMarin Pharmaceuticals | |
Raja Padidela MBBS, MRCPCH, MD (faculty) | Advisor, Consultant, Independent Contractor, Researcher, Speaker | Krowa Kirin, Alexion, Ultragenyx, Mereo |
Steven Petak MD JD (faculty) | Speaker | Alexion, Kyowa Kirin |
Dorothy Caputo, MA, BSN, RN - President | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Orakle LLC Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance

Facebook
X
LinkedIn
Forward